Oruka Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Oruka Therapeutics, Inc. (ORKA) reported Cash and Cash Equivalents, Period Increase (Decrease) of $3.36 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-01.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-01
- Oruka Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $1.96M.
- Oruka Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $1.40M, a 58.81% decline year-over-year.
- Oruka Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$1.45M, a 358.57% decline year-over-year.
- Oruka Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$1.58M.
- Oruka Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$2.09M, a 260.95% decline from fiscal 2017.
- Oruka Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $1.30M.
- Oruka Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$1.40M, a 110.13% decline from fiscal 2013.
- Oruka Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2013 was $13.84M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 114 month | Cash and Cash Equivalents, Period Increase (Decrease) 117 month | Cash and Cash Equivalents, Period Increase (Decrease) 120 month | Cash and Cash Equivalents, Period Increase (Decrease) 123 month | Cash and Cash Equivalents, Period Increase (Decrease) 126 month | Cash and Cash Equivalents, Period Increase (Decrease) 129 month | Cash and Cash Equivalents, Period Increase (Decrease) 132 month | Cash and Cash Equivalents, Period Increase (Decrease) 135 month | Cash and Cash Equivalents, Period Increase (Decrease) 138 month | Cash and Cash Equivalents, Period Increase (Decrease) 141 month | Cash and Cash Equivalents, Period Increase (Decrease) 144 month | Cash and Cash Equivalents, Period Increase (Decrease) 147 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $3.36M 10-Q · filed 2019-08-01 | $1.91M derived: sum of 3 quarters · filed 2019-08-01 | $331.00K derived: sum of 4 quarters · filed 2019-08-01 | ||||||||||||
| 2019-03-31 | $1.40M 10-Q · filed 2019-05-08 | -$50.00K derived: sum of 2 quarters · filed 2019-05-08 | -$1.63M derived: sum of 3 quarters · filed 2019-05-08 | -$4.09M derived: sum of 4 quarters · filed 2019-08-01 | ||||||||||||
| 2018-12-31 | -$1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$3.03M derived: sum of 2 quarters · filed 2019-02-27 | -$5.49M derived: sum of 3 quarters · filed 2019-08-01 | -$2.09M 10-K · filed 2019-02-27 | ||||||||||||
| 2018-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$4.04M derived: sum of 2 quarters · filed 2019-08-01 | -$646.00K 10-Q · filed 2018-11-14 | -$86.00K derived: sum of 4 quarters · filed 2019-08-01 | ||||||||||||
| 2018-06-30 | -$2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $933.00K 10-Q · filed 2019-08-01 | $1.49M derived: sum of 3 quarters · filed 2019-08-01 | $534.00K derived: sum of 4 quarters · filed 2019-08-01 | ||||||||||||
| 2018-03-31 | $3.39M 10-Q · filed 2019-05-08 | $3.95M derived: sum of 2 quarters · filed 2019-05-08 | $3.00M derived: sum of 3 quarters · filed 2019-05-08 | |||||||||||||
| 2017-12-31 | $560.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$399.00K derived: sum of 2 quarters · filed 2019-02-27 | $1.30M 10-K · filed 2019-02-27 | |||||||||||||
| 2017-09-30 | -$959.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $741.00K 10-Q · filed 2018-11-14 | ||||||||||||||
| 2017-06-30 | $1.70M 10-Q · filed 2018-08-09 | |||||||||||||||
| 2015-06-30 | $31.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $28.73M 10-Q · filed 2015-08-11 | $26.84M derived: sum of 3 quarters · filed 2015-08-11 | $24.71M derived: sum of 4 quarters · filed 2015-08-11 | ||||||||||||
| 2015-03-31 | -$3.17M 10-Q · filed 2015-05-12 | -$5.07M derived: sum of 2 quarters · filed 2015-05-12 | -$7.19M derived: sum of 3 quarters · filed 2015-05-12 | -$9.02M derived: sum of 4 quarters · filed 2015-08-11 | ||||||||||||
| 2014-12-31 | -$1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | -$4.02M derived: sum of 2 quarters · filed 2015-03-19 | -$5.85M derived: sum of 3 quarters · filed 2015-08-11 | -$1.40M 10-K · filed 2015-03-19 | ||||||||||||
| 2014-09-30 | -$2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$3.95M derived: sum of 2 quarters · filed 2015-08-11 | $493.00K 10-Q · filed 2014-11-12 | -$1.38M derived: sum of 4 quarters · filed 2015-08-11 | ||||||||||||
| 2014-06-30 | -$1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $2.62M 10-Q · filed 2015-08-11 | $745.00K derived: sum of 3 quarters · filed 2015-08-11 | -$997.00K derived: sum of 4 quarters · filed 2015-08-11 | ||||||||||||
| 2014-03-31 | $4.45M 10-Q · filed 2015-05-12 | $2.57M derived: sum of 2 quarters · filed 2015-05-12 | $828.00K derived: sum of 3 quarters · filed 2015-05-12 | $17.66M derived: sum of 4 quarters · filed 2015-05-12 | $21.20M 10-Q · filed 2014-05-13 | |||||||||||
| 2013-12-31 | -$1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | -$3.62M derived: sum of 2 quarters · filed 2015-03-19 | $13.22M derived: sum of 3 quarters · filed 2015-03-19 | $13.84M 10-K · filed 2015-03-19 | $16.76M 10-K · filed 2014-03-20 | |||||||||||
| 2013-09-30 | -$1.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $15.10M derived: sum of 2 quarters · filed 2014-11-12 | $15.71M 10-Q · filed 2014-11-12 | $15.55M derived: sum of 4 quarters · filed 2014-11-12 | $18.63M 10-Q · filed 2013-11-13 | |||||||||||
| 2013-06-30 | $16.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | $17.45M 10-Q · filed 2014-08-13 | $17.29M derived: sum of 3 quarters · filed 2014-08-13 | $17.19M derived: sum of 4 quarters · filed 2014-08-13 | $20.37M 10-Q · filed 2013-08-13 | |||||||||||
| 2013-03-31 | $617.00K 10-Q · filed 2014-05-13 | $456.00K derived: sum of 2 quarters · filed 2014-05-13 | $355.00K derived: sum of 3 quarters · filed 2014-05-13 | -$690.00K derived: sum of 4 quarters · filed 2014-05-13 | $3.54M 10-Q · filed 2013-05-13 | |||||||||||
| 2012-12-31 | -$161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | -$262.00K derived: sum of 2 quarters · filed 2014-03-20 | -$1.31M derived: sum of 3 quarters · filed 2014-03-20 | -$3.02M 10-K · filed 2014-03-20 | $2.92M 10-K · filed 2013-03-21 | |||||||||||
| 2012-09-30 | -$101.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | -$1.15M derived: sum of 2 quarters · filed 2013-11-13 | -$2.86M 10-Q · filed 2013-11-13 | -$2.67M derived: sum of 4 quarters · filed 2013-11-13 | $3.08M 10-Q · filed 2012-11-13 | |||||||||||
| 2012-06-30 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13 | -$2.76M 10-Q · filed 2013-08-13 | -$2.57M derived: sum of 3 quarters · filed 2013-08-13 | -$4.28M derived: sum of 4 quarters · filed 2013-08-13 | $3.18M 10-Q · filed 2012-08-13 | |||||||||||
| 2012-03-31 | -$1.72M 10-Q · filed 2013-05-13 | -$1.52M derived: sum of 2 quarters · filed 2013-05-13 | -$3.24M derived: sum of 3 quarters · filed 2013-05-13 | -$858.00K derived: sum of 4 quarters · filed 2013-05-13 | $4.23M 10-Q · filed 2012-05-14 | |||||||||||
| 2011-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-21 | -$1.52M derived: sum of 2 quarters · filed 2013-03-21 | $858.00K derived: sum of 3 quarters · filed 2013-03-21 | -$1.08M 10-K · filed 2013-03-21 | $5.94M 10-K · filed 2012-03-27 | |||||||||||
| 2011-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13 | $663.00K derived: sum of 2 quarters · filed 2012-11-13 | -$1.28M 10-Q · filed 2012-11-13 | -$2.16M derived: sum of 4 quarters · filed 2012-11-13 | $5.75M 10-Q · filed 2011-11-14 | |||||||||||
| 2011-06-30 | $2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | $438.00K 10-Q · filed 2012-08-13 | -$443.00K derived: sum of 3 quarters · filed 2012-08-13 | -$2.45M derived: sum of 4 quarters · filed 2012-08-13 | $7.46M 10-Q · filed 2011-08-15 | |||||||||||
| 2011-03-31 | -$1.94M 10-Q · filed 2012-05-14 | -$2.82M derived: sum of 2 quarters · filed 2012-05-14 | -$4.83M derived: sum of 3 quarters · filed 2012-05-14 | |||||||||||||
| 2010-12-31 | -$881.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-27 | -$2.89M derived: sum of 2 quarters · filed 2012-03-27 | -$738.00K 10-K · filed 2012-03-27 | |||||||||||||
| 2010-09-30 | -$2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $143.00K 10-Q · filed 2011-11-14 | ||||||||||||||
| 2010-06-30 | $2.15M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |